NASDAQ:ALT
Altimmune, Inc.
Altimmune, Inc.'s revenue grew 105.0% in fiscal 2025 to $41,000 while operating margin rose to −230461.0%. Free cash flow was −$67.5M, −164746.3% of revenue, and the diluted share count rose 24.1%.Summary generated from Altimmune, Inc.'s SEC filings. Latest annual report filed Mar 6, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$41,000
Revenue growth+105.0%
Revenue, 5-yr CAGR−65.3%
Gross marginn/a
Operating margin−230461.0%
Net margin−214861.0%
ROICn/a
Return on equity−50.6%
Debt / equity0.15
Free cash flow−$67.5M
FCF margin−164746.3%
Share count change+24.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 | −0 | 0 | 0 | 0 |
| Operating income | −97 | −88 | −96 | −103 | −94 |
| Net income | −97 | −85 | −88 | −95 | −88 |
| Free cash flow | −90 | −63 | −76 | n/a | −68 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KDirector or officer change
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KRegulation FD disclosure
Jul 28, 2026 - 8-KOther events
Jun 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026